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Editor’s key points
† Some supraglottic airway
devices (SADs) can be
used as a conduit for
fibreoptic-guided
tracheal intubation.
† This study evaluated two
SADs in 160 patients with
risk factors for difficult
intubation.
† Success of fibreoptic
intubation was .90%
overall, and similar using
the i-gelTM and sILMATM.
† Seal pressure was lower
with the i-gelTM, but there
were no other major
differences between
devices.
Background. The i-gelTM is a single-use supraglottic airway device (SAD) that allows
fibreoptic-guided tracheal intubation through the device. Until now, no prospective data
for this procedure are available. Therefore, in a prospective randomized controlled trial,
we evaluated fibreoptic-guided tracheal intubation with a standard Ru¨schTM PVC tracheal
tube (TT) through the i-gelTM compared with the single-use ILMATM (sILMATM) TT through
the sILMATM in patients with a predicted difficult airway.
Methods. With ethics committee approval and written informed consent, 160 patients were
randomly assigned to either SAD. After placement of the SAD, a fibreoptic bronchoscope
was introduced into the trachea as a railroad for the TT. Primary outcome variable was
the first-attempt fibreoptic-guided intubation success rate. Secondary variables included
time for insertion and intubation, airway leak pressures, fibreoptic view, and adverse
events. Data are presented as mean (SD) or percentages. A P-value of ,0.05 was
considered statistically significant.
Results. Fibreoptic-guided intubation was successful at the first attempt in 76 patients
(96%) using the i-gelTM and in 71 patients (90%) using the sILMATM (P¼0.21). Most of the
failed intubations were rescued by conventional laryngoscopy. Airway leak pressure was
higher for the sILMATM. There were no problems during removal of either type of SAD.
Conclusions. Fibreopic-guided tracheal intubation through the i-gelTM using a standard
Ru¨schTM Magill TT is successful and an alternative to the sILMATM with the sILMATM TT.
Keywords: airway, complications; anaesthetic techniques, fibreoptic intubation; intubation,
tracheal, laryngeal mask airway supraglottic airway devices
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The i-gelTM (Intersurgical Ltd, Wokingham, Berkshire, UK) has
proved popular with anaesthetists since its introduction into
clinical practice. Its large airway diameter enables the intro-
duction of a tracheal tube (TT) through the device.1 2 The use
of a fibreoptic scope has been recommended, but this has
never been studied in a prospective randomized controlled
trial in humans.
The single-use intubating laryngeal mask airway (sILMATM,
The Laryngeal Mask Company Limited, Le Rocher, Victoria,
Mahe´, Seychelles) with its corresponding ILMATM TT plays
an important role in the emergency pathway of various diffi-
cult airway algorithms.3 4 Success rate for tracheal intubation
using the reusable ILMATM is up to 93% with the aid of a
fibreoptic scope.5
Until now, there was only one trial in manikins6 evaluat-
ing the performance of intubation through the i-gelTM com-
pared with the reusable ILMATM. The success rate of
intubation through the ILMATM is high, but so are the
costs. Therefore, use of the ILMATM in clinical practice may
be limited to the unexpected difficult airway scenario. Clin-
icians initially may rely on the i-gelTM and then face the
need to convert to a tracheal airway. In this case, they
must know whether fibreopic-guided intubation through
the i-gel is feasible.
† These authors contributed equally to this work and share the first authorship.
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Therefore, in this prospective, randomized, controlled,
patient-blinded trial, we compared fibreoptic-guided tracheal
intubation through the i-gelTM using a conventional, curved
Magill tracheal PVC tube (Super SafetyClear, Ru¨sch GmbH,
Kernen, Germany) with the single-use ILMATM (sILMATM) with
its commercially available sILMATM PVC TT. Our hypothesis
was that there would be a difference of no more than 15%
between the two supraglottic airway devices (SADs) for the
first-attempt success rate of fibreopic-guided intubation.
Methods
Participants and anaesthesia
With written informed consent and ethics committee
approval (Cantonal Ethics Committee Bern, Bern, Switzerland,
approval number 79/08, August 29, 2008, ClinicalTrials.gov
identifier: NCT00888875), 160 patients were included.
Inclusion criteria were ASA physical status class I–IV, age
18–85 yr, undergoing elective surgery requiring tracheal
intubation at the University Hospital of Bern, and showing
at least one independent risk factor for a difficult airway.
Independent risk factors for a difficult airway included
documented difficult intubation in patient history, obesity
with BMI .30 kg m22, thyromental distance ,6 cm, inability
to protrude the mandible or retrognathia, abnormal neck
anatomy, modified Mallampati score .II,7 8 or mouth
opening ,3.5 cm.
Exclusion criteria were high risk of aspiration (non-fasted,
gastrooesophageal reflux disease), weight ,30 kg, known dif-
ficult mask ventilation, mouth opening ,20 mm,9 oral carci-
noma or bleeding that restricted the use of SADs, or patients
who did not speak German or who declined to participate.
The patients were blinded as to group allocation. We used
online computer randomization (www.randomization.com)
and sealed, opaque envelopes for randomization procedures.
In group 1, we inserted an i-gelTM and fibreoptically intubated
the trachea with a Ru¨schTM Magill PVC TT. In group 2, we
inserted an sILMATM and fibreoptic intubation was performed
with an sILMATM TT. The last 40 patients underwent one visu-
alized blind intubation attempt with the alternative TT
(Ru¨schTM TT for sILMATM, and sILMATM TT for i-gelTM) before
the fibreopic-guided intubation attempt was performed. The
data from these last 40 patients are also included in an
accompanying study.10 The primary outcome was success
rate of fibreoptic intubation at the first attempt.
Airway management was performed under supervision of
one of the senior study authors by staff anaesthesiologists
with experience in the use of the i-gelTM, the ILMATM, and
in fibreoptic-guided tracheal intubation.
All patients received midazolam 7.5 mg orally 30 min
before induction of anaesthesia. After institution of rec-
ommended anaesthetic monitoring, anaesthesia was
induced with propofol 1.0–2.5 mg kg21 and fentanyl 2–3 mg
kg21, and maintained with i.v. propofol to keep BIS 40–60.
No neuromuscular blocking drugs were given before SAD
insertion. After loss of the eye lash reflex, bag-mask venti-
lation was provided (maintaining SpO2 .96%, and steady
values of endexpiratory′ CO2). Then, the lubricated i-gelTM or
sILMATM was introduced according to randomization group.
A stable head position was obtained with a doughnut-shaped
pillow throughout the study. The head was maintained in the
neutral position for insertion of the sILMATM and with the neck
extended for insertion of the i-gelTM. After insertion of the SAD
and completing all measurements related to the SAD, neuro-
muscular blocking drugs were administered to decrease the
incidence of coughing during intubation, and to reduce com-
plications during SAD removal.11
SAD insertion
SAD insertion was performed according to the manufacturer’s
recommendations12 13 with small adjustments for size
selection: a size 3 sILMATM was chosen for patients weighing
30–50 kg, a size 4 for 50–70 kg, and a size 5 for patients
.70 kg. For the i-gelTM, a size 3 was used for patients weigh-
ing 30–50 kg (up to 60 kg, if patient’s height was ,160 cm),
size 4 for 60–90 kg (down to 50 kg, if patient’s height was
.160 cm), and size 5 for patients .90 kg. This adaptation
for the i-gelTM for patients in the weight range 50–60 kg
was made to avoid the overlap between sizes 3 and 4. K-Y
Lubricating Jelly (Johnson & Johnson Medical Limited, Gar-
grave, Skipton, UK) was used in all SADs. The cuff of the
sILMATM was fully deflated during insertion, and then inflated
to a maximum of 60 cm H2O,
13 using a manometer (Ru¨schTM
GmbH, Kernen, Germany).
An initial assessment of ventilation was made by gently
squeezing the reservoir bag and observing end-tidal carbon
dioxide waveforms and chest movements. In the case of
adequate ventilation, leak pressure was measured as
described below. Adequate ventilation was defined as two
consecutive tidal volumes of at least 6 ml kg21 ideal body
weight (height in cm–100) during pressure-controlled venti-
lation at 17 cm H2O.
14 15
In the case of inadequate ventilation, up to three minor
airway interventions were allowed (e.g. adjusting head/neck
position, changing depth of insertion).16 If the first SAD
failed after three insertion attempts, the other SAD was
used, again allowing three insertion attempts and minor
airway manoeuvres.14
Time necessary for insertion was measured from the time
the face mask was taken away from the face until the
appearance of CO2 on the capnograph.
Intubation
A fibrescope (Acutronic Medical Systems AG, Hirzel,
Switzerland) was primed with a lubricated size 7.0 mm
Ru¨schTM Magill PVC TT or a lubricated 7.0 mm sILMATM TT
according to randomization (Ru¨sch PVC tube in the case of
i-gelTM, sILMATM tube in the case of sILMATM). After preoxy-
genation of the patient’s lungs, and when neuromuscular
block was confirmed by loss of twitch response to nerve
stimulation (train-of-four stimulation, TOF-WatchwSX,
Organon Teknika AG, Pfa¨ffikon, Switzerland), the breathing
system was briefly disconnected and the TT and fibrescope
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inserted through the airway port. We graded best fibreoptic
view on the glottis from the outlet of the SAD from 1 to 4
(1, vocal cords entirely visible; 2, vocal cords or arytenoid car-
tilages partially visible; 3, epiglottis only visible; 4, no laryn-
geal structures visible) as previously proposed.17 After
intubation with the fibrescope, the TT was railroaded into
the trachea. To pass the epiglottic elevating bar in the case
of the sILMATM, the TT was inserted to the 15 cm depth
mark (black line) and advanced beyond the epiglottic elevat-
ing bar of the sILMATM together with the scope (tube first
technique). Then, the larynx was seen and the fibreoptic
scope was advanced into the trachea. The tip of the TT
pointed upwards, so the black writing on the tube faced pos-
teriorly.13 To facilitate advancement of the TT over the
fibreoptic scope, the following manoeuvres were permitted:
anticlockwise rotation of the TT by 908, the SAD adjusted
by ‘Chandy’ manoeuvres,5 13 by the ‘up-down’ manoeuvre,
or by changing the inclination of the patient’s head. These
adjustments of the SAD were also allowed if the fibrescope
could not be inserted into the trachea, but not for the
initial evaluation of fibreoptic view.5 If fibreoptic intubation
failed, either the alternative SAD was used or the airway
was secured according to the attending anaesthesiologists
decision. The position of the TT in the trachea was verified
fibreoptically. Our primary outcome variable was the first-
attempt success rate of fibreoptic-guided tracheal intuba-
tion. Success was defined as end-tidal carbon dioxide con-
firmed placement of the TT within a maximum of 5 min
tracheal intubation time.5
After intubation, the fibrescope was removed and the
breathing circuit reconnected to the tube. Intubation time
was measured from the time the breathing circuit was dis-
connected until the carbon dioxide curve appeared again
on the monitor. An additional time point was set when the
glottis was passed with the scope (time necessary to intu-
bate the trachea with the fibrescope).
To remove the SADs, we used the sILMATM stabilizer rod for
both SADs, according to the ILMATM user booklet.13 Time to
remove the SAD was measured from disconnection of the
breathing system until reappearance of the carbon dioxide
curve on the monitor. At this time, the study was finished
and anaesthesia was maintained according to the attending
anaesthesiologist.
Airway leak pressure
Airway leak pressure was measured by closing the expiratory
valve of the circle breathing system at a fixed gas flow of 3
litres min21 and noting the airway pressure (max. allowed
40 cm H2O) at which equilibrium was reached or air was
leaking audibly.18 Air entering the stomach was detected
by auscultation over the epigastrium when measuring oro-
pharyngeal leak.14
Adverse events
All adverse events were recorded, defined as suspicion of
aspiration/regurgitation (gastric fluid in the ventilation tube
or in the hypopharynx), hypoxia (SpO2 ,92%), hypotension
(mean arterial pressure ,55 mm Hg), hypertension (mean
arterial pressure ±20% over pre-induction baseline),
changes in heart rate ±20%, pre-induction value, broncho-
spasm, airway obstruction, coughing, dental, tongue, or lip
trauma.
Evaluation of postoperative complaints
On postoperative day 1, an investigator who was blinded to
patient allocation, anaesthesia, and the performance of
airway management interviewed the patient to obtain data
about side-effects. In the case of ambulatory surgery, we
called the patients by phone. Asked items included: sore
throat, hoarseness, dysphagia, postoperative nausea and
vomiting, rescue medication, pain, analgesics taken, and
any unscheduled re-hospitalization.
Statistical analysis
There are no clinical trials prospectively evaluating fibreoptic
intubation through the i-gelTM SAD in humans. Joo and Rose5
showed a 93% first-attempt success when intubating
through the ILMATM using a fibreoptic scope. Pandit and col-
leagues19 had an 80% first-attempt success when fibreoptic-
guided intubation was performed via the classic LMA and an
outright failure of 10% because of the aperture bars. A clini-
cally significant difference in success of 15% was assumed in
a study (ILMATM vs C-TrachTM) by Liu and colleagues20 in
accordance with the data of Pandit and colleagues19 who
found a difference of 15% comparing fibreoptic intubation
through ILMATM vs the classic LMATM. On the basis of our
experience with the i-gelTM, we expected the difference of
the fibreoptically guided tracheal intubation success rate to
be ,15%, and calculated that a sample of 160 patients
was necessary, given a¼0.05 and a power of 80%.
For our primary outcome variable, the success rate of
fibreoptic-guided tracheal intubation, and other frequency
data, we compared values using the x2 test. The SADs were
evaluated as intention-to-treat according to randomization.
Continuous data were analysed using the Mann–Whitney
test if normality distribution could not be assumed; other-
wise Student’s t-test was used. We analysed all data with
SPSS V.15 (SPSS Inc., Chicago, IL, USA/SPSS Schweiz AG,
Zu¨rich, Switzerland). Data are presented as mean (SD), or per-
centage. A probability value of ,0.05 was considered stat-
istically significant.
Results
One hundred and sixty-five patients were undergoing
general anaesthesia with tracheal intubation and presented
at least one predictor of difficult airway management
during the 349 days of the study. Four patients did not give
informed consent. One was not randomized because of
changes in surgical procedure, and so 160 patients were ran-
domized, 91 (57%) of whom were male (Fig. 1). Twenty-two
anaesthetists participated in the study. There were no differ-
ences in baseline patient characteristics (Table 1).
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Face-mask ventilation was deemed to be easy in 108
cases, in the other 52 cases either two-handed ventilation
or a Guedel airway was necessary. Vital signs did not differ
significantly between the two SADs throughout the study.
Insertion of the SADs
We found no difference in the insertion success rates
between i-gelTM and sILMATM (P¼1.00, Table 2). In one case
of insufficient ventilation with an sILMATM, the airway was
secured by oral intubation. One i-gelTM failed because of
inadequate ventilation without hypoxia. This patient’s lungs
were ventilated successfully using the sILMATM.
One i-gelTM had to be changed from size 4 to 5 in a male
patient of 88 kg and 173 cm and one sILMATM had to be
changed from size 4 to 5 in another male of 67 kg and 174
cm because of excessive airway leaks, although the size
selection was according to the manufacturer’s descriptions.
There were no differences in first-attempt success rates
and rate of minor interventions necessary (Table 2). Time of
SAD insertion and tidal volumes between the two groups
were equivalent as well. Airway leak pressure was lower for
the i-gelTM compared with the sILMATM [mean (SD) 24 (8) vs
29 (7) cm H2O, P¼0.001].
Fibreoptic tracheal intubation
Ventilation failed with one i-gelTM and one sILMATM and the
airway had to be secured by other means. Fibreoptic intuba-
tion was attempted via 79 i-gelsTM and 79 sILMAsTM. There
was no statistically significant difference in the primary
outcome measure: the success rate at first attempt of
fibreoptically guided tracheal intubation was 76 (96%)
using the i-gelTM with the Magill PVC TT compared with 71
(90%) using the sILMATM with its sILMATM TT (P¼0.21,
Table 3).
There was no difference in fibreoptic laryngeal view
(P¼0.42). Epiglottic downfolding was more frequent in the
sILMATM compared with the i-gelTM (16% vs 1%, P¼0.01).
The mean time necessary for intubation was 72 (42) s for
the i-gelTM group and 65 (37) s for the sILMATM group
(P¼0.34). The time necessary for the fibrescope to intubate
the trachea did not differ significantly between i-gel and
sILMATM (P¼0.54). However, the time to railroad the tubes
over the fibrescopes varied greatly between the two SADs
[i-gelTM: mean 28 (17) s, sILMATM: mean 18 (15) s, P,0.001].
The three patients in the i-gelTM group in whom fibreoptic
intubation was impossible despite correction manoeuvres all
underwent tracheal intubation using conventional
Screened patients
undergoing general
anaesthesia requiring
intubation: 1945
No inclusion criteria: 1780Patients withinclusion criteria: 165
Given informed consent: 161 Declined to participate: 4
Randomized: 160Not randomized: 1(changed surgical procedure)
1 i-gel failure, solution:
sILMA
80 insertions of i-gel
Success: 79
80 insertions of sILMA
Success: 79
1 sILMA failure, solution:
Conventional intubation
8 not successful, solution:
7 conventional intubation
1 intubation via i-gel
sILMA removal possible: 71i-gel removal possible: 76
Fibreoptic intubation i-gel
Success: 76
3 not successful, solution:
Conventional intubation
Fibreoptic intubation sILMA
Success: 71
Fig 1 Study flowchart.
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laryngoscopy. The eight failed sILMATM intubations were
managed by conventional intubation seven times and once
by fibreoptic intubation through the i-gelTM (Fig. 1).
Removal of the SAD
All inserted SADs were removed without complications using
the sILMATM exchange rod. There was no difference in
removal time between the SADs [39 (13) s for the i-gelTM
compared with 40 (16) s for the sILMATM, P¼0.624].
Adverse events and postoperative complaints
We found no differences in haemodynamic changes during
insertion or intubation between the groups. Four i-gelsTM
(5%) and two sILMAsTM (3%) were stained with blood after
removal (P¼0.65).
Desaturation (SpO2 ,90%) occurred in one obese patient
(BMI 37 kg m22) after induction of anaesthesia and before
insertion of the SAD despite 3 min preoxygenation. Face-
mask ventilation was established quickly and SpO2 recovered
promptly. There were no other adverse events.
The incidence of postoperative sore throat was 14%
(i-gelTM) and 9% (sILMATM), respectively, P¼0.45. There
were no other postoperative complaints.
Discussion
In this prospective, randomized, controlled, patient-blinded
clinical trial, we found equally high success rates for
fibreopic-guided tracheal intubation with the Ru¨schTM Magill
TT via the i-gelTM, and with the single-use ILMATM TT via the
sILMATM in a patient population with predictors of difficult
airway management.
The fibreoptic-guided intubation with the Ru¨schTM Magill TT
through the i-gelTM failed in only 4%. The 90% success rate for
the sILMATM group was slightly lower than the 93% described
earlier for the reusable ILMATM.5 This might be attributed to our
study population presenting predictors of difficult airway man-
agement or to the different material of the single-use ILMATM
(PVC) and the reusable ILMATM (silicone). However, an earlier
comparison of the reusable and the single-use ILMATM in 84
patients with normal airway anatomy found the performance
of both devices to be equal.21 The few failed fibreoptic intuba-
tions were evenly distributed among the anaesthesiologists
and we did not find an influence of the anaesthesiologist on
the time necessary for intubation. Also, our post hoc analysis
detected no decrease in intubation time over the study
course, indicating the absence of a learning curve.
There was no statistically significant difference in the intu-
bation success rate between i-gelTM and sILMATM (96% vs
90%, P¼0.211). The 95% confidence interval of this differ-
ence in success rate was 22% to 15%. We do not know to
what extent the success rate would have changed if we
had used an sILMATM TT with the i-gelTM, but this was not
the goal of the study. The differences in success rates using
different TTs with the ILMATM have been studied by others,
Table 1 Patient characteristics and perioperative data, presented
as mean (SD) or number
i-gelTM1Ru¨sch
PVC tube (n580)
sILMATM1sILMATM
tube (n580)
Age (yr) 56 (21–85) 57 (22–83)
Gender (M/F) 24/56 45/35
ASA I/II/III/IV 11/41/28/0 6/37/35/2
Height (cm) 173 (9) 168 (8)
Weight (kg) 90 (18) 88 (19)
BMI (kg m22) 30 (6) 31 (4)
Patients with BMI .30
kg m22
41 45
Thyromental distance
,6 cm
9 7
No jaw protrusion 2 2
Presence of sleep
apnoea
44 34
Mallampati I/II/III 26/38/16 31/35/14
Mouth opening ,3.5
cm
9 7
Mask ventilation
possible without help
54 53
Duration of surgery
(min)
140 (99) 139 (81)
Duration of
anaesthesia (min)
226 (120) 226 (100)
Table 2 SAD insertion, presented as mean (SD) or number.
*P,0.001 between the groups
i-gelTM
(n580)
sILMATM
(n580)
Success at first attempt 75 75
Overall success 79 79
Minor intervention necessary 20 16
Time of insertion (s) 23 (15) 28 (23)
Tidal volume (ml) 668 (242) 655 (230)
Airway leak pressure (cm H2O) 24 (8) 29 (7)*
Table 3 Fibreoptic intubation through the SADs, presented as
mean (SD) or number. *P,0.01. †Laryngeal view was graded from
1 to 4 (1, vocal cords entirely visible; 2, vocal cords or arytenoid
cartilages partially visible; 3, epiglottis only visible; 4, no laryngeal
structures visible)16
i-gelTM
(n579)
sILMATM
(n579)
Fibreoptic intubation successful at first
attempt
76 71
Laryngeal view 1/2/3/4† 54/12/7/6 47/14/13/4
Epiglottic downfolding 1 13*
Time for intubation (s) 72 (42) 65 (37)
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with inconclusive results.5 22 – 24 It took longer to railroad the
Ru¨schTM Magill PVC TT over the intubated fibrescope. We
speculate that the softer tip of the sILMA TMTT allowed
easier advancement.25
Our study confirmed the high airway seal pressures for
both SADs which were published by other study groups.5 26
Airway leak pressures for the sILMATM were higher than pre-
viously reported for the reusable ILMATM.27
Postoperative complaints were rare and we did not find
any statistically significant differences between the two
airway sets. However, there was a statistically not significant
difference in the incidence of postoperative sore throat with
the i-gelTM/Ru¨schTM PVC TT (14%) compared with the
sILMATM/sILMATM TT (9%, P¼0.45). Both the stiffness of the
Ru¨schTM PVC TT and the i-gelTM may have been contributing
factors.
As a limitation, this study was performed on patients with
predictors of difficult mask ventilation, difficult laryngoscopy,
and difficult intubation. Because of ethical considerations, we
did not include patients with a previously known difficult
airway, denying them the advantage of an awake fibreoptic
intubation. It is possible that the devices used in the
present study perform differently in patients with real diffi-
cult airway, but that was not in the scope of this study.
In the last 40 patients, a visualized blind intubation
attempt was performed before fibreoptic intubation (these
data are included in an accompanying study).10 This TT was
withdrawn, and the patients were intubated by fibreoptic gui-
dance according to the randomized airway device. To rule out
any potential effect of the blind intubation attempt on the
later fibreoptic intubation, we compared both subgroups
(the last 40 patients vs the first 120 patients) and found no
difference in time for fibreoptic intubation (P¼0.12 for the
i-gelTM and P¼0.38 for the sILMATM). There was no significant
difference in failure rate: 1.6% (i-gelTM) and 5% (sILMATM) in
the first 120 patients compared with 2.5% (i-gelTM) and 5%
(sILMATM) in the last 40 patients (P¼0.99).
In conclusion, we found that in 160 patients with predic-
tors for difficult airway management, fibreoptic-guided tra-
cheal intubation with a standard Ru¨schTM Magill PVC TT
through an i-gelTM was as successful as the use of an
sILMATM with its sILMATM TT. The i-gelTM and Ru¨schTM Magill
TT may be a reliable and cost-effective alternative to the
sILMATM with its sILMATM TT.
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